Healthcare Companies Receive Approvals, Recognitions, Agreements, and Announce Senior Level Appointments- Analyst Notes on Pfizer, Boston Scientific, WellPoint, Aetna, and Humana

NEW YORK, March 18, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE: PFE), Boston Scientific Corporation (NYSE: BSX), WellPoint Inc. (NYSE: WLP), Aetna Inc. (NYSE: AET), and Humana Inc. (NYSE: HUM). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Pfizer  Inc.  Analyst  Notes

On March 12, 2014, Pfizer Inc. (Pfizer) issued a press release confirming that the United States District Court for the Eastern District of Virginia granted summary judgment invalidating the reissue patent (U.S. Patent No. RE44, 048), covering methods of treating osteoarthritis and other approved conditions with celecoxib, the active ingredient in Celebrex®. According to the press release, the Company disagrees with the ruling and will pursue all available remedies including an immediate appeal of the court's decision. Additionally, Pfizer stated that a trial was scheduled to begin on March 19, 2014 for infringement of the reissue patent in the action brought by Pfizer against a few generic companies. These generic companies had previously filed an abbreviated new drug application with the US FDA seeking approval to market a generic form of celecoxib in the US beginning on May 30, 2014, when Pfizer's basic Celebrex® compound patent (including the six-month pediatric exclusivity period)expires. The full analyst notes on Pfizer Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03182014/PFE/report.pdf

Boston  Scientific  Corporation  Analyst  Notes

On March 12, 2014, Boston Scientific Corporation (Boston Scientific) announced that it has received CE Mark approval for the REBEL™ Platinum Chromium Coronary Stent System, the Company's last generation bare metal stent for the treatment of coronary artery disease (CAD). Kevin Ballinger, President, Interventional Cardiology, Boston Scientific stated, "Boston Scientific is committed to advancing cardiology and providing the best treatment options for all patients with coronary artery disease. This includes innovating and improving the performance of bare metal stent technology to enhance patient outcomes." The full analyst notes on Boston Scientific Corporation are available to download free of charge at:

http://www.AnalystsReview.com/03182014/BSX/report.pdf

WellPoint  Inc.  Analyst  Notes

On March 11, 2014, WellPoint Inc. (WellPoint) announced that the Company has won a Bronze Stevie Award in the Sales Training or Coaching Program of the Year category in the 8th  Annual  Stevie  Awards  for  Sales  &  Customer  Service. According to WellPoint, the Bronze Stevie Award recognizes the Company's eight-week Compass  New  Hire  Program for reinforcing foundational selling skills. Commenting on the honor, Ken Goulet, Executive Vice President, President, Commercial and Specialty Business, WellPoint, stated, "Our sales training program for new hires is top-notch, and helped contribute to significant growth in our commercial and specialty membership in January 2014. Being recognized as a Stevie Award winner is a well-deserved honor for our sales training teams." The full analyst notes on WellPoint Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03182014/WLP/report.pdf

Aetna  Inc.  Analyst  Notes

On March 11, 2014, Aetna Inc. (Aetna) along with Atlantic Accountable Care Organization (Atlantic ACO), a partner of Atlantic Health System, announced a new accountable care agreement that will improve the coordination and delivery of patient care. According to the Company, Aetna members who use the Atlantic ACO and Centers of Excellence will experience more coordinated care, particularly those patients with chronic and complex conditions. Additionally, the Company stated that Aetna members will also have enhanced access to appropriate care and will benefit from the improved flow of information to treating physicians in the Atlantic ACO. "Aetna will work closely with the ACO physicians to identify specific areas where we can either develop or improve on the sharing of specific, useful health information. In turn, the physicians will use this information to improve care for patients, close gaps in care and reduce waste. We are creating a continuous loop of improved information to drive better care. By working together, we can bring better health, better care and better cost to thousands of Aetna members beginning this spring," said John Lawrence, President of Aetna. The full analyst notes on Aetna Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03182014/AET/report.pdf

Humana  Inc.  Analyst  Notes

On March 6, 2014, Humana Inc. (Humana) announced that it has appointed Christopher Kay, as Senior Vice President and Chief Innovation Officer, effective March 17, 2014. According to Humana, Kay will report to President and CEO Bruce Broussard and will also serve on the Company's Management Team. Additionally, Humana stated that Kay will lead the Company's innovation strategy and will focus on innovations in personalized health designed to simplify the health care experience, leading to better health outcomes. Commenting on the appointment, Broussard stated, "Chris is a keen innovator with a passion for creating new businesses in large organizations, and for launching products and services that enhance the consumer experience. He brings a wealth of experience in consumer-facing industries to a pivotal role that is vital to Humana's future success." The full analyst notes on Humana Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03182014/HUM/report.pdf

About Analysts Review

We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

=============

EDITOR  NOTES:

• This is not company news. We are an independent source and our views do not reflect the companies mentioned.
• Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
• This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
• If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
• For  any  urgent  concerns  or  inquiries, please contact us at compliance [at] AnalystsReview.com.
• Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.

COMPLIANCE  PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT  FINANCIAL  ADVICE

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO  WARRANTY  OR  LIABILITY  ASSUMED

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://www.AnalystsReview.com

SOURCE Analysts Review